Antibody discovery platform
MilleGen has developed and patented (5 patents) new and innovative technologies involved in each phase of the recombinant antibodies discovery process.
MilleGen's technology platform allows generation from a new human monoclonal antibody library and high-affinity improvement of recombinant antibody candidates. Our team provides a whole range of skills from the cloning steps of antibody recombinant fragments to the selection and expression of the whole fully human antibody molecule.
Click on figure to enlarge
